Loading company…
Vaccine Company develops preclinical vaccine candidates for infectious diseases.
Vaccine Company develops vaccine candidates using its In Vivo Nanoparticle technologies, which combine elements of mRNA and virus-like particle approaches. Its preclinical programs include a candidate intended to prevent infectious mononucleosis caused by Epstein-Barr virus. Founded in 2022 and based in the US, it agreed to be acquired by Eli Lilly & Company from ARCH Venture Partners in May 2026 for up to USD 1.55 billion in contingent sales-based milestones.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in